

PD-L1 Expression by IHC

UROTHELIAL CANCER

Overview

- Up to 77,000 patients in the U.S. are expected to be diagnosed with bladder cancer in 2016¹, and the most common type is urothelial carcinoma.²
- The five-year relative survival of patients with metastatic urothelial cancer (mUC) is poor at 5%.³
- Systemic chemotherapy is the standard first-line approach for patients with metastatic urothelial malignancies⁴ and with inoperable locally advanced disease⁵. Although initial response rates are high, the median survival with chemotherapy is approximately 15 months.^{5,6}
- Currently there is no standard therapy for second-line chemotherapy⁴ and thus, for patients who do relapse, the prognosis may be poor. The need to improve outcomes has led to the evaluation of new targeted agents, including immune checkpoint inhibitors.

PD-L1 Expression and Immunotherapy

An ongoing Phase II clinical trial (IMvigor 210 trial) is evaluating second-line treatment of TECENTRIQ™ (atezolizumab) in mUC patients who have progressed after chemotherapy. New data has shown that tumors with high PD-L1 expression levels (IC2/3) correlated with improved overall response rates and median overall survival (OS), and the response to treatment was durable.^{7,8}

The VENTANA® anti-PD-L1 (SP142) IHC assay was recently FDA-approved as a complementary diagnostic assay which may help identify locally advanced or metastatic urothelial cancer patients more likely to respond to treatment with TECENTRIQ™ (atezolizumab).⁹

PD-L1 Status	N (%)	Overall Response Rate, %	Median OS, Months	12-Month OS, %
IC2/3 (≥5%)	100 (32%)	26%	11.4	48%
IC1 (≥1% but <5%)	210 (68%)	10%	6.7	30%
IC0 (<1%)		8%		
All	310 (100%)	15%	7.9%	36%

IC=PD-L1 expression on tumor-infiltrating immune cells, response rates are usually around 10% with second-line standard chemotherapy

Specimen Requirement Options

Global Only

Tissue should be fixed in 10% neutral buffered formalin for a fixative time of at least 6 hours. Fixative times less than 6 hours results in a significant loss of staining intensity. Other fixatives are not recommended.

1) Fixed Paraffin Block with Corresponding H&E

2) Unstained Slides:

- Minimum of 4 slides (include additional slide for H&E)
- Pre-cut slides from paraffin block in 4-5 micron sections and mount on plus (+) slides. Slides should be less than 2 months after sectioning if stored at 15-30°C.



More than **490,000** tests performed on **225,000+** patients annually

1,600 contractual relationships with plans, payors, and other health care organizations across the US, some of which are on an exclusive basis



Integrated with **more than 700** electronic medical records (EMR) and practice management systems

Menu of **more than 450** genetic, pathology, IHC, and FISH tests, including 15 oncology-specific pharmacogenetic tests



Staff of **more than 75** pathologists, PhDs, and genetic counselors dedicated to oncology and familial cancer testing

More than 65 oncology- and pathology-specific publications and presentations since 2013



Lab Locations

Arizona

Integrated Oncology
5005 South 40th Street
Phoenix, AZ 85040
800-710-1800
Fax 800-481-4151

New York

Integrated Oncology
521 West 57th Street, Sixth Floor
New York, NY 10019
800-447-5816
Fax 212-258-2143

North Carolina

LabCorp Center for Molecular
Biology and Pathology
1912 Alexander Drive
Research Triangle Park, NC 27709
800-345-4363
Fax 919-361-7798

Tennessee

Integrated Oncology
201 Summit View Drive, Suite 100
Brentwood, TN 37027
800-874-8532
Fax 615-370-8074

REFERENCES

1. American Cancer Society. *Cancer Facts & Figures 2016*. Atlanta: American Cancer Society; 2016, page 22.
2. National Cancer Institute website. <http://www.cancer.gov/types/bladder>. Accessed 4/8/2016
3. SEER Stat Fact Sheets: Bladder Cancer. Website <http://seer.cancer.gov/statfacts/html/urinb.html>. Accessed 4/8/2016.
4. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (Version 1.2016). ©2016 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed 4/11/2016.
5. Von der Maase, H et al., Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. *J Clin Oncol* 2000; 18:3068-77.
6. Von der Maase, H et al., Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. *J Clin Oncol* 2005; 23:4602-8.
7. Hoffman-Censits, JH et al., IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). *J Clin Oncol* 34, 2016 (suppl2S; abstr 355).
8. Genitourinary Cancers Symposium Daily News. IMvigor 210: Atezolizumab Offers Potential of Durable mUC Suppression After Failure of Platinum-Based Treatment. Website <http://gucasym.org/daily-news/imvigor-210-atezolizumab-offers-potential-durable-muc-suppression-after-failure-platinum>. Accessed 4/11/2016.
9. FDA News Release, May 18, 2016. Accessed on FDA website 5/19/16. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm>.



LabCorp Specialty Testing Group

VENTANA® is a registered trademark of Roche Diagnostics International, LTD.
TECENTRIQ™ is a trademark of Genentech, Inc.
©2016 Laboratory Corporation of America® Holdings. All rights reserved.
onc-904-v1-0516
L15517-0516-1

www.integratedoncology.com